CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The Two Key Trends Of AI In Biotechnology

The Two Key Trends Of AI In...

Compound K', Is Fast Absorbing And Has A Higher Immune-Boosting Effect Than Ginseng

Compound K', Is Fast Absorbing And...

Informa Pharma Intelligence announces the launch of its Citeline Connect

Informa Pharma Intelligence announces...

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

How Does Biotechnology Help the World

How Does Biotechnology Help the World

Pharma and Biotech are Looking to Cloud and AI to Expediate Drug Discovery

Pharma and Biotech are Looking to...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

How AI Enhances Biotech Operations

How AI Enhances Biotech Operations

The Two Key Trends Of AI In Biotechnology

The Two Key Trends Of AI In...

Compound K', Is Fast Absorbing And Has A Higher Immune-Boosting Effect Than Ginseng

Compound K', Is Fast Absorbing And...

Informa Pharma Intelligence announces the launch of its Citeline Connect

Informa Pharma Intelligence announces...

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

How Does Biotechnology Help the World

How Does Biotechnology Help the World

Pharma and Biotech are Looking to Cloud and AI to Expediate Drug Discovery

Pharma and Biotech are Looking to...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

How AI Enhances Biotech Operations

How AI Enhances Biotech Operations

CVasThera Raises 1.9 M in its First Round of Funding

Life Sciences Review | Monday, August 23, 2021
Tweet

The company’s equity and capital would be tripled as a result of these funds. It will allow CVasThera to fund preclinical trials for its CVT120165 molecule, which is a Crohn’s disease drug candidate.


FREMONT, CA: CVasThera, a biopharmaceutical firm specializing in the advancement of new treatments for cardiovascular and bowel diseases, announced today that it has raised 1.3 million dollars ($1.6 million) in the first round of Funding. The company’s equity and capital would be tripled as a result of these funds. It will allow CVasThera to fund preclinical trials for its CVT120165 molecule, which is a Crohn’s disease drug candidate. Safety results from phase I trials with healthy subjects, which were completed in 2008 for another indication, are already available. In 2022, the firm intends to go forward with a pilot phase II experiment with Crohn’s patients.


The company’s primary investor is OCSEED, a venture capital firm based in France’s Occitanie region that is making its first investment in the company. In the form of convertible bonds, this infusion of funds would provide CVasThera with the equity funding it wants to go forward with clinical trials and expand its pharmaceutical research and development team. The remaining funds will come from the company’s investors, who will contribute long-term and working capital, as well as a Bpifrance investment loan, financing from the Occitanie region, and a partnership with the French National Research Agency.


Corticosteroids are the treatment of choice for Crohn’s patients with mild to serious flare-ups. However, there are a variety of risks to these medications that hinder their use. There is a substantial medical need for a therapy that will eliminate inflammatory flare-ups and restore the structural damage to the intestine lining of early-diagnosed Crohn’s patients, in addition to corticosteroids.


CVasThera’s lead drug candidate is a game-changing breakthrough that has the potential to close a critical void in the therapeutic arsenal for Crohn’s disease. Rather than rebuilding the weakened intestinal tissue, most current therapies aim to reduce the inflammatory response. The CVT120165 compound, on the other hand, has a special mechanism of action that restores intestinal tissue damage and relieves patients’ painful symptoms. Perhaps more novel is the fact that the compound directly attacks the damaged tissue.


The molecule is stored in a proprietary capsule that allows the drug to be reabsorbed and adhered to weakened tissue in the intestine. This combination of two supplementary mechanisms repair and targeted treatment makes CVT120165 an up-and-coming option for Crohn’s patients.


While several firms are focused on new approaches to mitigate inflammatory flare-ups, the CVasThera project is the only one that aims to reverse the disease’s tissue damage. It’s still the only PAR-1 antagonist in clinical trials for curing Crohn’s flare-ups and avoiding relapses. According to CVasThera’s figures, Crohn’s disease patients represent a 4 billion dollars (3.3 billion) industry in the United States and Europe, which is rising at a rate of 0.3 percent per year. The disease’s diagnosis and prevalence rates are also growing at a fast pace.


Weekly Brief

loading
Top 10 Biotech Startups in APAC - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/cvasthera-raises-19-m-in-its-first-round-of-funding-nwid-291.html